Is Jeena Sikho overvalued or undervalued?

As of May 19, 2025, Jeena Sikho is considered very expensive with a PE ratio of 61.03 and high valuation metrics, despite outperforming the Sensex with a 102.02% return over the past year, indicating it is overvalued compared to industry norms and some competitors.

As of 19 May 2025, the valuation grade for Jeena Sikho has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 61.03, a Price to Book Value of 28.80, and an EV to EBITDA ratio of 43.82, all of which are considerably high compared to industry norms. <BR><BR>In comparison to its peers, Max Healthcare Institute Ltd. has a PE ratio of 100.29 and an EV to EBITDA of 62.71, while Apollo Hospitals Enterprise Ltd. shows a PE of 69.03 and an EV to EBITDA of 34.71, indicating that Jeena Sikho, despite its high ratios, is still less expensive than some of its competitors. Notably, Jeena Sikho has outperformed the Sensex over the past year with a return of 102.02%, compared to the Sensex's 7.86%, but this strong performance does not justify its current valuation levels.

What does Jeena Sikho do?

Jeena Sikho Lifecare Ltd is a mid-cap company in the hospital industry, incorporated in 2017 and converted to a public company in 2021. It has a market cap of Rs 5,668 Cr, with a P/E ratio of 61.00 and a return on equity of 47.20%.

Overview: <BR>Jeena Sikho Lifecare Ltd operates in the hospital industry and is categorized as a mid-cap company.<BR><BR>History: <BR>Jeena Sikho Lifecare Ltd was originally incorporated as a Private Limited Company on May 29, 2017, and later converted into a Public Limited Company, with a name change to "Jeena Sikho Lifecare Limited" on July 05, 2021. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: Rs 5,668 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 61.00 <BR>Industry P/E: 54 <BR>Dividend Yield: 0.18% <BR>Debt-Equity: -0.34 <BR>Return on Equity: 47.20% <BR>Price-to-Book: 28.69 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: Not available <BR>Email: Not available <BR>Website: Not available

What is the bonus history of the Jeena Sikho?

Jeena Sikho Lifecare Ltd has announced a bonus issue of 4:5, with an ex-date of November 2, 2023. Shareholders will receive four additional shares for every five shares held as of the record date.

Jeena Sikho Lifecare Ltd recently announced a bonus issue with a ratio of 4:5, and the ex-date for this bonus is set for November 2, 2023. This means that shareholders will receive four additional shares for every five shares they hold as of the record date. If you have any more questions about the company or its financial activities, feel free to ask!

Has Jeena Sikho declared dividend?

Jeena Sikho Lifecare Ltd has declared a 41% dividend, amounting to 4.1 per share, with an ex-date of August 20, 2024. While the company has shown significant long-term returns, recent performance has been mixed, with a total return of -3.85% over the last six months.

Jeena Sikho Lifecare Ltd has declared a 41% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 41%<BR>- Amount per share: 4.1<BR>- Ex-date: 20 Aug 24<BR><BR>Dividend Yield: 0.18%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -3.85%, with a dividend return of 0%, resulting in a total return of -3.85%.<BR><BR>Over the past year, the price return was 113.33%, with a dividend return of 0.39%, leading to a total return of 113.72%.<BR><BR>In the two-year period, the price return was 743.87%, with a dividend return of 2.35%, culminating in a total return of 746.22%.<BR><BR>For the three-year period, the price return was 2643.14%, with a dividend return of 8.10%, resulting in a total return of 2651.24%.<BR><BR>In the four-year period, there was no price return and no dividend return, leading to a total return of 0.0%.<BR><BR>Over the five-year period, there was also no price return and no dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, Jeena Sikho Lifecare Ltd has declared a significant dividend, but the total returns over the last several periods show a mixed performance, with substantial gains in longer time frames but some recent volatility.

Who are the peers of the Jeena Sikho?

Jeena Sikho's peers include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, and others. Fortis Health has the highest 1-year return at 59.53%, while Jeena Sikho's return is 0.00%.

Peers: The peers of Jeena Sikho are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Yatharth Hospit., Indrapr.Medical, Artemis Medicare, Dr Agarwal's Eye, and Shalby.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Indrapr.Medical, and the rest. Good growth is seen in Max Healthcare, Apollo Hospitals, Narayana Hrudaya, and the rest, while Average growth is found at Fortis Health., Yatharth Hospit., Dr Agarwal's Eye, Shalby, and the rest. Excellent capital structure is noted at Max Healthcare, Global Health, Indrapr.Medical, and the rest, while Average capital structure is present at Apollo Hospitals, Artemis Medicare, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fortis Health. at 59.53%, while Shalby has the lowest at -28.92%. Jeena Sikho's 1-year return is 0.00%, which is significantly lower than both. Additionally, Global Health, Yatharth Hospit., Indrapr.Medical, Artemis Medicare, and Shalby have negative six-month returns.

Who are in the management team of Jeena Sikho?

As of March 2023, the management team of Jeena Sikho includes Manish Grover (Executive Director), Bhavna Grover (Whole-time Director), Shreya Grover, Suraj Prakash Choudhary, and Karan Vir Bindra (all Non-Executive Directors), and Nikita Juneja (Company Secretary), with varying remuneration levels. The team reflects a diverse governance structure with both executive and non-executive roles.

As of March 2023, the management team of Jeena Sikho includes:<BR><BR>1. Manish Grover - Executive Director (Remuneration: INR 2.4 crore)<BR>2. Bhavna Grover - Whole-time Director (Remuneration: INR 1.8 crore)<BR>3. Shreya Grover - Non Executive Director (Remuneration: INR 0)<BR>4. Suraj Prakash Choudhary - Non Executive Director (Remuneration: INR 1.44 lakhs)<BR>5. Karan Vir Bindra - Non Executive Director (Remuneration: INR 1.44 lakhs)<BR>6. Nikita Juneja - Company Secretary & Compliance Officer (Remuneration: INR 3.0 lakhs)<BR><BR>This team comprises a mix of executive and non-executive roles, reflecting a diverse governance structure within the company.

Who are the top shareholders of the Jeena Sikho?

The top shareholders of Jeena Sikho include Manish Grover with 63.27%, Oregano Life Private Limited at 5.8%, and 12 foreign institutional investors holding a combined 5.91%. Individual investors own 17.05%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Jeena Sikho include the promoters, with Manish Grover holding the highest share at 63.27%. Additionally, Oregano Life Private Limited is the largest public shareholder, owning 5.8%. The company also has 12 foreign institutional investors (FIIs) that collectively hold 5.91% of the shares, while individual investors account for 17.05% of the holdings. There are no pledged promoter holdings, and no mutual funds currently hold shares in the company.

How big is Jeena Sikho?

As of 24th July, Jeena Sikho Lifecare Ltd has a market capitalization of 6,680.00 Cr, classifying it as a Mid Cap company. There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.

As of 24th July, <BR><BR>Market Cap: Jeena Sikho Lifecare Ltd has a market capitalization of 6,680.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2023, with Shareholder's Funds amounting to 125.80 Cr and Total Assets totaling 150.59 Cr.

When is the next results date for Jeena Sikho?

The next results date for Jeena Sikho is November 6, 2025.

The next results date for Jeena Sikho is scheduled for November 6, 2025.

How has been the historical performance of Jeena Sikho?

Jeena Sikho experienced significant growth from March 2022 to March 2023, with net sales increasing to 204.75 Cr from 146.55 Cr, and profit after tax rising to 33.52 Cr from 11.19 Cr, reflecting strong improvements in operating profit margins and overall financial performance. Total assets also grew to 150.59 Cr, while cash flow showed a positive turnaround.

Answer:<BR>The historical performance of Jeena Sikho shows significant growth in various financial metrics from March 2022 to March 2023.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2023, Jeena Sikho reported net sales of 204.75 Cr, a notable increase from 146.55 Cr in the previous year. Total operating income mirrored this growth, reaching 204.75 Cr compared to 146.55 Cr in March 2022. The total expenditure, excluding depreciation, rose to 159.15 Cr from 128.50 Cr, while operating profit (PBDIT) surged to 48.20 Cr from 19.54 Cr, indicating a robust operating profit margin improvement from 12.32% to 22.27%. Profit before tax also saw a substantial rise to 44.29 Cr from 15.09 Cr, leading to a profit after tax of 33.52 Cr, up from 11.19 Cr, resulting in a PAT margin increase from 7.64% to 16.37%. The company's total assets grew to 150.59 Cr from 61.54 Cr, with total liabilities increasing to 150.59 Cr from 61.54 Cr. Cash flow from operating activities decreased slightly to 14.00 Cr from 16.00 Cr, but net cash inflow improved significantly to 29.00 Cr from a net outflow of 6.00 Cr, reflecting a strong closing cash position of 31.00 Cr compared to 2.00 Cr the previous year. Overall, Jeena Sikho demonstrated a strong upward trend in financial performance across key metrics.

Should I buy, sell or hold Jeena Sikho?

Is Jeena Sikho technically bullish or bearish?

As of November 25, 2025, Jeena Sikho's trend has shifted to sideways, indicating a neutral stance with mixed signals from key indicators, including a mildly bearish outlook from Dow Theory and a mildly bullish trend in On-Balance Volume.

As of 25 November 2025, the technical trend for Jeena Sikho has changed from mildly bearish to sideways. The current stance is neutral, reflecting a lack of strong directional movement. Key indicators include a mildly bearish outlook from Dow Theory on the weekly timeframe, while the On-Balance Volume (OBV) shows a mildly bullish trend on the weekly basis. The MACD, RSI, and other indicators do not provide clear signals at this time. Overall, the stock's recent performance shows a slight gain over the past week, contrasting with a decline over the past month.

Which are the latest news on Jeena Sikho?

Why is Jeena Sikho falling/rising?

As of 04-Dec, Jeena Sikho Lifecare Ltd's stock price is rising, currently at 699.30, indicating a potential trend reversal after recent declines. While there is short-term recovery and increased institutional interest, the stock has underperformed over the past week and month, raising concerns about its valuation.

As of 04-Dec, Jeena Sikho Lifecare Ltd's stock price is rising, currently at 699.30, reflecting a change of 3.15 (0.45%) upward. This increase comes after two consecutive days of decline, indicating a potential trend reversal. The stock has outperformed its sector by 0.58% today, suggesting a positive shift in market sentiment.<BR><BR>Despite the recent rise, the stock has been underperforming over the past week, with a decline of 4.73%, while the benchmark Sensex fell only 0.53%. Over the past month, Jeena Sikho's stock has decreased by 10.58%, contrasting with a 2.16% increase in the Sensex. This indicates that while the stock is experiencing a short-term rise, it has faced significant challenges recently.<BR><BR>Investor participation has been falling, as evidenced by a 37.07% drop in delivery volume compared to the five-day average. However, there has been an increase in institutional investor participation, with a 0.57% rise in their stake over the previous quarter, which may provide some support for the stock's price.<BR><BR>Financially, the company shows strong growth metrics, with net sales growing at an annual rate of 37.80% and operating profit increasing by 66.94%. Additionally, the company has a low debt-to-equity ratio of 0.05, which is favorable. However, the stock is considered expensive with a price-to-book value of 31.9 and a PEG ratio of 7, which may deter some investors.<BR><BR>In summary, the stock's current rise can be attributed to a short-term recovery after previous declines, positive sector performance, and increasing institutional interest, despite ongoing concerns regarding its valuation and recent investor participation trends.